Trial Profile
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Feb 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Aug 2015 Planned initiation date changed from 1 Jun 2014 to 1 Jul 2015, as reported by ClinicalTrials.gov.
- 07 Jul 2014 Planned primary completion date changed to 1 Jun 2017.